Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Holy Cross Hospital
Fort Lauderdale, Florida, United States
- Providence Medical Group
Terre Haute, Indiana, United States
- Norton Cancer Institute
Louisville, Kentucky, United States
- Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, United States
- Portsmouth Regional Hospital
Portsmouth, New Hampshire, United States
- Tennessee Oncology
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2009
- Primary completion
- 30 Nov 2012
- Completion
- 31 May 2013
- Last update posted
- 6 Dec 2021
- Registered enrollment
- 4
- Registry id
- NCT00960297
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.